These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 6580841

  • 21. Vindesine. A phase II trial in advanced breast cancer patients.
    Robins HI, Tormey DC, Skelley MJ, Falkson G, Crowley JJ, Ramirez G, Falkson H.
    Cancer Clin Trials; 1981; 4(4):371-5. PubMed ID: 7318120
    [Abstract] [Full Text] [Related]

  • 22. [A cooperative phase II study of vindesine sulfate in patients with solid tumors].
    Gan To Kagaku Ryoho; 1983 Sep; 10(9):2036-42. PubMed ID: 6614938
    [Abstract] [Full Text] [Related]

  • 23. Vindesine: a phase II study in childhood malignancies-a report for cancer and leukemia group B.
    Ettinger LJ, Brecher M, Coleman M, Smithson WA, Patterson R, Russell EC, Necheles T, Jones B, Ohnuma T.
    Med Pediatr Oncol; 1982 Sep; 10(1):35-43. PubMed ID: 7038420
    [Abstract] [Full Text] [Related]

  • 24. Phase II study of vindesine in patients with metastatic breast cancer.
    Cobleigh MA, Williams SD, Einhorn LH.
    Cancer Treat Rep; 1981 Sep; 65(7-8):659-63. PubMed ID: 7248983
    [Abstract] [Full Text] [Related]

  • 25. [Phase II study of etoposide (VP-16) in the form of intravenous injection for malignant lymphomas and acute leukemias: Hanshin Cooperative Study Group for Hematological Disorders].
    Tagawa S, Kitani T, Nagai K, Kanamaru A, Kohsaki M, Masaoka T, Shibata H, Horiuchi A, Tsubaki K, Kawagoe H.
    Gan No Rinsho; 1987 Jan; 33(1):1-7. PubMed ID: 3469424
    [Abstract] [Full Text] [Related]

  • 26. [Vindesine, a new cytostatic agent from the vinca alkaloids].
    Goldhirsch A, Joss R, Sonntag RW, Brunner KW.
    Dtsch Med Wochenschr; 1980 Jun 27; 105(26):931-5. PubMed ID: 6931709
    [No Abstract] [Full Text] [Related]

  • 27. Phase II evaluation of vindesine in mycosis fungoides, extraosseous plasmacytoma and other hematologic malignancies.
    Ferrazzi E, Pappagallo GL, Segati R, Vinante O, Galligioni E, Zagonel V, Salvagno L, Fiorentino MV.
    Tumori; 1982 Aug 27; 68(4):321-4. PubMed ID: 7147357
    [Abstract] [Full Text] [Related]

  • 28. Broad phase II study of vindesine.
    Valdivieso M, Bedikian AY, Bodey GP, Freireich EJ.
    Cancer Treat Rep; 1981 Aug 27; 65(9-10):877-9. PubMed ID: 7273021
    [Abstract] [Full Text] [Related]

  • 29. [Phase II study of vindesine in patients with primary bronchogenic carcinoma by Cooperative Study Group].
    Gan To Kagaku Ryoho; 1983 Aug 27; 10(8):1838-43. PubMed ID: 6882007
    [Abstract] [Full Text] [Related]

  • 30. [Personal experience on the chemotherapy of leukemias and hematosarcomas].
    Mathé G, Schneider M, Schwarzenberg L, Cattan A, Amiel JL, Schlumberger JR.
    Acta Genet Med Gemellol (Roma); 1968 Jan 27; 17(1):245-54. PubMed ID: 4874537
    [No Abstract] [Full Text] [Related]

  • 31. Vindesine in the treatment of malignant mesothelioma: a phase II study.
    Kelsen D, Gralla R, Cheng E, Martini N.
    Cancer Treat Rep; 1983 Sep 27; 67(9):821-2. PubMed ID: 6883358
    [Abstract] [Full Text] [Related]

  • 32. Initial clinical study with vindesine: tolerance to weekly iv bolus and 24-hour infusion.
    Ohnuma T, Greenspan EM, Holland JF.
    Cancer Treat Rep; 1980 Jan 27; 64(1):25-30. PubMed ID: 6929728
    [Abstract] [Full Text] [Related]

  • 33. Vindesine for metastatic malignant melanoma. A phase II trial.
    Nelimark RA, Peterson BA, Vosika GJ, Conroy JA.
    Am J Clin Oncol; 1983 Oct 27; 6(5):561-4. PubMed ID: 6613921
    [Abstract] [Full Text] [Related]

  • 34. Rubidazone in adults with previously treated acute leukemia and blast cell phase of chronic myelocytic leukemia: a Southwest Oncology Group Study.
    Bickers J, Benjamin R, Wilson H, Eyre H, Hewlett J, McCredie K.
    Cancer Treat Rep; 1981 Oct 27; 65(5-6):427-30. PubMed ID: 6940659
    [Abstract] [Full Text] [Related]

  • 35. [Phase-II-study with vindesine (desacetyl-vinblastine-amide-sulfate) in advanced malignant diseases].
    Goldhirsch A, Beer M, Sonntag RW, Tschopp L, Cavalli F, Ryssel HJ, Brunner KW.
    Schweiz Med Wochenschr; 1980 Jul 08; 110(27-28):1063-7. PubMed ID: 7423151
    [Abstract] [Full Text] [Related]

  • 36. [A presumed transient hemolytic reaction following vinca alkaloids administration in patients with hematological malignancies].
    Iwata N, Wakamatsu E, Oike S, Umegae S, Omine M, Maekawa T, Tsuchiya J.
    Rinsho Ketsueki; 1984 May 08; 25(5):649-54. PubMed ID: 6590896
    [No Abstract] [Full Text] [Related]

  • 37. A study of the cross-resistance of vincristine and vindesine in reinduction therapy for acute lymphocytic leukemia in relapse. A report for Children's Cancer Study Group.
    Krivit W, Anderson J, Chilcote R, Pyesmany A, Chard R, Hammond D.
    Am J Pediatr Hematol Oncol; 1980 May 08; 2(3):217-21. PubMed ID: 7001942
    [Abstract] [Full Text] [Related]

  • 38. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
    Early AP, Preisler HD, Slocum H, Rustum YM.
    Cancer Res; 1982 Apr 08; 42(4):1587-94. PubMed ID: 6949642
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. [Early phase II trial of bestrabucil in hematological malignancies].
    Nagura E, Ohno R, Yamada K, Akao Y, Naito K, Nishikawa M, Tanaka H, Shirakawa S, Ono Y, Ezaki K.
    Gan To Kagaku Ryoho; 1986 Jun 08; 13(6):2216-22. PubMed ID: 3459398
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.